Last reviewed · How we verify

Alprostadil 20 micrograms

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Phase 2 active Small molecule

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation.

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation. Used for Peripheral arterial occlusive disease, Intermittent claudication, Critical limb ischemia.

At a glance

Generic nameAlprostadil 20 micrograms
SponsorFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Drug classProstaglandin E1 analog
TargetProstanoid receptors (EP receptors)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Alprostadil binds to prostanoid receptors on vascular smooth muscle and platelets, triggering increased intracellular cAMP levels. This leads to relaxation of vascular smooth muscle (vasodilation), improved blood flow, and reduced platelet clumping. These effects improve tissue perfusion and oxygenation in ischemic conditions.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: